Bristol-Myers Squibb Co (LTS:0R1F)
$ 59.4 -0.61 (-1.02%) Market Cap: 119.70 Bil Enterprise Value: 163.01 Bil PE Ratio: 0 PB Ratio: 6.98 GF Score: 82/100

Bristol-Myers Squibb Co at Bank of America Healthcare Conference Transcript

May 11, 2022 / 07:00PM GMT
Release Date Price: $75.83 (-2.13%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

To the afternoon session of the Bank of America Healthcare Conference. My name is Geoff Meacham, I'm the senior biopharma analyst here. And we're thrilled today on stage have Bristol-Myers and speaking up of Bristol is Adam Lenkowsky, who is Senior Vice President, General Manager, U.S. Commercial. Adam, welcome.

Adam Lenkowsky
Bristol-Myers Squibb Company - Head of U.S. Oncology

Thank you, Geoff, and thank you so much for having me here. It's a pleasure to be here. As Geoff said, I lead our U.S. commercial organization at BMS. I have responsibility for our oncology, immunology and cardiovascular portfolio. I've been with Bristol now for 25 years and had the great pleasure of those 25 years to have responsibility about half of the time for our oncology portfolio.

So launching Yervoy in the U.S., launching Opdivo, and Opdivo and Yervoy worldwide. And I got to say in my 25 years, this is probably the most exciting time in the time I've been here, with the recent approval

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot